Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists

  • Bioorg Med Chem Lett. 2015 Mar 15;25(6):1196-205. doi: 10.1016/j.bmcl.2015.01.066.
Hao Zhang  1 Charles Z Ding  1 Zhi Lai  1 Sean S Chen  1 Pratik Devasthale  1 Tim Herpin  1 George Morton  1 Fucheng Qu  1 Denis Ryono  1 Rebecca Smirk  1 Wei Wang  1 Shung Wu  1 Xiang-Xang Ye  1 Yi-Xin Li  2 Atsu Apedo  2 Dennis Farrelly  3 Tao Wang  4 Liqun Gu  3 Nathan Morgan  3 Neil Flynn  3 Cuixia Chu  3 Lori Kunselman  3 Jonathan Lippy  4 Kenneth Locke  4 Kevin O'Malley  4 Thomas Harrity  3 Michael Cap  3 Lisa Zhang  5 Vinayak Hosagrahara  5 Pathanjali Kadiyala  5 Carrie Xu  5 Arthur M Doweyko  6 Robert Zahler  1 Narayanan Hariharan  3 Peter T W Cheng  1
Affiliations
  • 1. Metabolic Diseases Chemistry, Bristol-Myers Squibb Research and Development (R&D), Princeton, NJ 08543-5400, USA.
  • 2. Discovery Analytical Sciences, Bristol-Myers Squibb R&D, Princeton, NJ 08543-5400, USA.
  • 3. Metabolic Diseases Biology, Bristol-Myers Squibb R&D, Princeton, NJ 08543-5400, USA.
  • 4. Lead Evaluation, Bristol-Myers Squibb R&D, Princeton, NJ 08543-5400, USA.
  • 5. Metabolism and Pharmacokinetics, Bristol-Myers Squibb R&D, Princeton, NJ 08543-5400, USA.
  • 6. Computer-Assisted Drug Design, Bristol-Myers Squibb R&D, Princeton, NJ 08543-5400, USA.
Abstract

The design, synthesis and structure-activity relationships of a novel series of 3,4-disubstituted pyrrolidine acid analogs as PPAR ligands is outlined. In both the 1,3- and 1,4-oxybenzyl pyrrolidine acid series, the preferred stereochemistry was shown to be the cis-3R,4S isomer, as exemplified by the potent dual PPARα/γ agonists 3k and 4i. The N-4-trifluoromethyl-pyrimidinyl pyrrolidine acid analog 4i was efficacious in lowering fasting glucose and triglyceride levels in diabetic db/db mice.

Keywords
Dual agonists; Peroxisome Proliferator-Activated Receptor; Pyrrolidine acid; Type 2 diabetes.